Falcone Marco, Pompeo Maria Elena, Fabi Flavia, Venditti Mario
Dipartimento di Medicina Clinica, Policlinico Umberto I, Universita degli Studi di Roma La Sapienza, Italy.
Infez Med. 2008 Jun;16(2):94-8.
Treatment of Nocardia infections continues to be difficult, especially for central nervous system infections or disseminated diseases and when sustained by highly drug-resistant species such as Nocardia farcinica. Linezolid, the first oxazolidinone approved for clinical use, shows an excellent in vitro activity against all species of Nocardia, and achieves good central nervous system and lung concentrations. We describe the case of a patient with pulmonary nocardiosis and intolerance to trimethoprim/sulfamethoxazole successfully treated with linezolid, and review all the published cases of systemic nocardiosis treated with this agent. On the basis of the available evidence, linezolid appears an effective option for the treatment of nocardiosis.
诺卡菌感染的治疗仍然困难重重，尤其是对于中枢神经系统感染或播散性疾病，以及由高耐药菌种如豚鼠耳炎诺卡菌引起的感染。利奈唑胺是首个获批用于临床的恶唑烷酮类药物，对所有诺卡菌属菌种均显示出优异的体外活性，并且在中枢神经系统和肺部可达到良好的浓度。我们描述了1例患有肺诺卡菌病且对甲氧苄啶/磺胺甲恶唑不耐受的患者成功接受利奈唑胺治疗的病例，并回顾了所有已发表的使用该药物治疗系统性诺卡菌病的病例。基于现有证据，利奈唑胺似乎是治疗诺卡菌病的一种有效选择。
